TY  - JOUR
AU  - Zhang, Yiyao
AU  - Liu, Lizhen
AU  - Fan, Pei
AU  - Bauer, Nathalie
AU  - Gladkich, Jury
AU  - Ryschich, Eduard
AU  - Bazhin, Alexandr V
AU  - Giese, Nathalia A
AU  - Strobel, Oliver
AU  - Hackert, Thilo
AU  - Hinz, Ulf
AU  - Gross, Matthias Wolfgang
AU  - Fortunato, Franco
AU  - Herr, Ingrid
TI  - Correction: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
JO  - OncoTarget
VL  - 15
IS  - 1
SN  - 1949-2553
CY  - [Erscheinungsort nicht ermittelbar]
PB  - Impact Journals LLC
M1  - DKFZ-2024-01494
SP  - 504 - 506
PY  - 2024
N1  - Original article: Oncotarget. 2015; 6:9999–10015. https://doi.org/10.18632/oncotarget.3171
KW  - Humans
KW  - Gemcitabine
KW  - Deoxycytidine: analogs & derivatives
KW  - Deoxycytidine: pharmacology
KW  - Deoxycytidine: therapeutic use
KW  - Pancreatic Neoplasms: drug therapy
KW  - Pancreatic Neoplasms: pathology
KW  - Pancreatic Neoplasms: metabolism
KW  - Drug Resistance, Neoplasm: drug effects
KW  - Aspirin: pharmacology
KW  - Aspirin: therapeutic use
KW  - Neoplastic Stem Cells: drug effects
KW  - Neoplastic Stem Cells: pathology
KW  - Neoplastic Stem Cells: metabolism
KW  - Antimetabolites, Antineoplastic: pharmacology
KW  - Gemcitabine (NLM Chemicals)
KW  - Deoxycytidine (NLM Chemicals)
KW  - Aspirin (NLM Chemicals)
KW  - Antimetabolites, Antineoplastic (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:39018218
DO  - DOI:10.18632/oncotarget.28527
UR  - https://inrepo02.dkfz.de/record/291690
ER  -